Search - Browse Site

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and both a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers (which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet). Allogeneic Immune Cell Generation Platform   Ability to manufacture immune effector cells (natural killer (NK) cells, macrophages) from cord blood derived CD34+ cells Truly universal – no HLA matching required Clinically Tested: Unmodified NK cells have been investigated in two phase 1 clinical trials   Universal SNAP-CAR   Antigen agnostic chimeric antigen receptor (CAR) platform Universal SNAP-CAR construct binds to tagged antibodies directing antigen specificity and allowing for use of multiple antigens in the same indication SNAP-CAR expression in a universal immune effector cell results in the ability to use ONE off-the-shelf SNAP-CAR cell bank for use with selected tagged antibodies across multiple indications such as hematological malignancies, solid tumors, and autoimmune diseases   GEAR Platform   GEAR: “Gene-Edited Antibody Resistant” cell engineering technology Gene editing of immune effector cells to prevent fratricide when using therapeutic antibodies GEAR editing does not impact normal function of non-modified cells   Development & Clinical Collaborations   University of Pittsburgh Karolinska Institute Deverra Therapeutics Fred Hutch Cancer Center Duke Cancer Institute Novant Health

Trxade Health, Inc. (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. The Company operates in the Healthcare space serving thousands of members nationwide, fostering price transparency, and maximizing supply chain efficiency. Trxade Health is a community of forward-thinkers, innovators, and healthcare enthusiasts. We are proud to facilitate connections that drive progress, efficiency, and ultimately, better health outcomes. Join us on this journey as we continue to redefine the future of healthcare through innovation and collaboration. Discover a new era in healthcare with Trxade Health , where your success and well-being are our top priorities. Relationships We have successfully created an environment that promotes and enhances the relationship between pharmaceutical buyers and sellers, and connect patients and practitioners at a lower cost and at their convenience. Choices Select from a variety of healthcare products and sources featuring clear pricing and AI tools that enhance the buying experience with business-critical advantages. Our ongoing objective is to maximize your efficiency. Analytics Our proprietary data analytics offer all echelons of the pharmaceutical supply chain advanced and actionable market intelligence. We are able to keep our finger on the pulse and react in real time to market trends and needs

"Why limit yourself to investing in just one industry when you can diversify your portfolio and maximize your returns with a single investment? Explore the endless possibilities and potential for growth by spreading your investments across multiple industries. Don't miss out on the opportunity to see your wealth grow exponentially with 1847 Holdings, LLC!" About 1847 Holdings LLC 1847 Holdings LLC (NYSE American: EFSH), a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue, and Principal of Lazard Freres Strategic Realty Investors. 1847 Holdings' investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises or lower-middle market businesses with limited exit options despite the intrinsic value of their business. Given this dynamic, 1847 Holdings can consistently acquire businesses it views as "solid" for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems of those businesses in order to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at higher valuations than the purchase price and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to 1847 Holdings' ability to pay regular and special dividends to shareholders. For more information, visit www.1847holdings.com . Our controlled buying model combines the most attractive attributes of owning private, lower middle market businesses, with the liquidity and transparency of a publicly traded company.   We are not lenders or minority owners. Our operational characteristics are based on simplicity, focus, speed, and flexibility. Our experience allows us to map the most profitable path forward, case by case for our portfolio companies, in close collaboration with management. We provide shareholders with non-correlated returns while allowing shareholders to liquidate their position in 1847 Holdings LLC at any point during an investment timeline. Our unique structure permits flow-through tax treatment for shareholders. As a result, 1847 will seek to generate returns for shareholders through consistent, annual distributions of operating subsidiary income and capital appreciation resulting from the timely sale of operating subsidiaries.

NAPC Defense, Inc. (BLIS): Fully Licensed Veteran-Owned Leaders in Armament Sales and Production NAPC Defense, Inc. (formerly known as Treasure & Shipwreck Recovery, Inc.), trading as (OTCPK: BLIS), announces that it has completed the change of name with the State of Nevada and registration with the State of Florida, as well as a new website at www.NAPCDefense.com . It is also finalizing its application with FINRA to effect all additional merger terms announced in the March 27, 2024 press release. NAPC Defense, Inc. owns defense and construction contracting firm Native American Price Constructors, LLC.

(CSE: PLAS) (Frankfurt: XV) PlasCred is revolutionizing the concept of waste by transforming plastic into a valuable resource, providing it with a second chance at life. Our mission is to propel the world towards a climate-positive future, positioning ourselves as a leading up cycling facility in North America and beyond. Through cutting-edge technology and groundbreaking innovation, PlasCred is reshaping the global approach to plastic waste management and recycling. We have a strategic vision for the future that centers on creating a positive environmental footprint and establishing ourselves as the pinnacle of environmental credits, encompassing both plastic and carbon credits.

With its strong foundation in manufacturing and innovative designs, LSEB Creative presents a compelling investment opportunity for those seeking growth in the fashion sector. The company is positioned for significant expansion as it taps into the growing global demand for high-quality and stylish swimwear.

Prenetics (NASDAQ: PRE), a leading genomics-driven health sciences company, is revolutionizing prevention, early detection, and treatment. Our prevention arm, CircleDNA, uses whole exome sequencing to offer the world’s most comprehensive consumer DNA test. Our $200 million joint venture with renowned scientist Prof. Dennis Lo, underscores our unwavering commitment to saving lives through pioneering multi-cancer early detection technologies. Lastly, ACT Genomics, our treatment unit, is the first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors via ACTOnco. Each of Prenetics’ units synergistically enhances our global impact on health, truly embodying our commitment to enhancing life through science.